Inventor · disambiguated record
Alexis Mikes Kalergis Parra
Also filed as: KALERGIS PARRA ALEXIS · KALERGIS PARRA ALEXIS MIKES
14 granted patents·3 pending applications·6 citations·filing 2008–2021
84Inventor score
Top patents by PatentIndex Score
17 records- 0174US8398993B2Immunogenic formulationKALERGIS PARRA ALEXIS MIKES·Filed 2008·Granted Mar 19, 2013·5 cites·18 claims
- 0270US9999663B2Immunogenic formulation containing recombinant live BCG that express antigens of metapneumovirus (hMPV), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical useUNIV PONTIFICIA CATOLICA CHILE·Filed 2014·Granted Jun 19, 2018·1 cites·13 claims
- 0364US11873331B2Monoclonal antibodies specifically for the antigen P of the human respiratory syncytial virus, produced and secreted by the cells hybridomas, useful for detection and diagnostic of the infection caused by RSVUNIV PONTIFICIA CATOLICA CHILE·Filed 2020·Granted Jan 16, 2024·0 cites·14 claims
- 0456US12247066B2Monoclonal antibody 14F5F6 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2UNIV PONTIFICIA CATOLICA CHILE·Filed 2018·Granted Mar 11, 2025·0 cites·14 claims
- 0556US12098185B2Monoclonal antibody 11B2C7 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2UNIV PONTIFICIA CATOLICA CHILE·Filed 2018·Granted Sep 24, 2024·0 cites·12 claims
- 0656US2024042012A1IMMUNOGENIC FORMULATION CONTAINING ONE OR MORE MODIFIED BCG STRAINS EXPRESSING A SARS-CoV-2 PROTEIN, USEFUL FOR PREVENTING, TREATING, OR ATTENUATING THE DEVELOPMENT OF COVID-19UNIV PONTIFICIA CATOLICA CHILE·Filed 2021·Application pending·0 cites
- 0755US2023390378A1Immunogenic formulation containing a modified bcg strain expressing an andesvirus protein (andv) useful for preventing and treating hanta-andv virus infectionsUNIV PONTIFICIA CATOLICA CHILE·Filed 2021·Application pending·0 cites
- 0854US10858419B2Monoclonal antibodies specifically for the antigen P of the human respiratory syncytial virus, produced and secreted by the cells hybridomas, useful for detection and diagnostic of the infection caused by RSVUNIV PONTIFICIA CATOLICA CHILE·Filed 2016·Granted Dec 8, 2020·0 cites·14 claims
- 0951US12195523B2Monoclonal antibody or antigen binding fragment thereof that binds to the L protein of the human parainfluenza virus (PIV); method and kit for detecting PIVUNIV PONTIFICIA CATOLICA CHILE·Filed 2019·Granted Jan 14, 2025·0 cites·9 claims
- 1051US12145980B2Monoclonal antibodies specific for the PB2 antigen of the human influenza A virus (flu), nucleotide sequences, method and diagnostic kit for flu infectionUNIV PONTIFICIA CATOLICA CHILE·Filed 2019·Granted Nov 19, 2024·0 cites·9 claims
- 1148US12065484B2Specific monoclonal antibody against the N antigen of human respiratory syncytial virus (hRSV) useful for treating infection, detection thereof and diagnosisUNIV PONTIFICIA CATOLICA CHILE·Filed 2018·Granted Aug 20, 2024·0 cites·12 claims
- 1244US9995747B2Specific monoclonal antibodies of the antigen M of the human metapneumovirus (HMPV) and use thereof in a diagnostic methodUNIV PONTIFICIA CATOLICA CHILE·Filed 2015·Granted Jun 12, 2018·0 cites·12 claims
- 1343US10766948B2Monoclonal antibodies specific for the pIII antigen of human Adenovirus (ADV), produced and secreted by cell hybridomas, useful for detection and diagnosis of ADV infectionUNIV PONTIFICIA CATOLICA CHILE·Filed 2017·Granted Sep 8, 2020·0 cites·18 claims
- 1443US9273122B2Monoclonal antibodies specific for the M2-1 antigen of respiratory syncytial virus (RSV)UNIV PONTIFICIA CATOLICA CHILE·Filed 2012·Granted Mar 1, 2016·0 cites·11 claims
- 1540US11085080B2Use of IL-3, IL-33 and IL-12p40 as markers for characterization of respiratory infections by respiratory syncytial virusUNIV PONTIFICIA CATOLICA CHILE·Filed 2016·Granted Aug 10, 2021·0 cites·2 claims
- 1635US11065301B2Pharmaceutical composition for ameliorating the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralizes the function of TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and use thereofUNIV PONTIFICIA CATOLICA CHILE·Filed 2016·Granted Jul 20, 2021·0 cites·6 claims
- 1735US2017196950A1Method for producing autologous tolerogenic dendritic cells (toldcs) with specific antigens and their use in the preparation of a medicament useful for the treatment of systemic lupus erythematosus (sle)UNIV PONTIFICIA CATOLICA CHILE·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Alexis Mikes Kalergis Parra files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →